Venus Remedies Share Price Jumps Over 10%; Here’s Why

Venus Remedies’ share price jumped over 10% as of 9:27 AM on January 21, 2025, reaching an intraday high of ₹332.40 on the NSE. Here’s why the stock is in the spotlight.

Key Update Driving the Surge

Venus Remedies Limited witnessed a sharp rise in its share price by over 10% following the announcement of a significant achievement. The company has successfully renewed its European Good Manufacturing Practices (GMP) certification, further solidifying its foothold in the European market. This milestone reaffirms the company’s dedication to delivering top-quality pharmaceutical solutions globally.

What Does the Certification Cover?

Granted by Infarmed, the National Authority of Medicines and Health Products in Portugal, this renewal certifies Venus Remedies’ facility for manufacturing:

• Cephalosporin formulations
• Carbapenem products
• Oncology liquid and lyophilised injectables

This certification ensures compliance with the strict manufacturing standards of the European Union, enhancing trust in the company’s product quality.

Impact on European Market Presence

Venus Remedies has been a consistent player in the European pharmaceutical landscape since its initial EU GMP certification in 2007. Over the last 15 years, the company has maintained a robust presence as a leading exporter of meropenem outside India, with multiple marketing authorisations across the region.

Share Market Reaction

The renewal of this certification signifies the company’s ability to sustain high standards. The market reacted positively, driving Venus Remedies’ share price upward, as it positions itself as a trusted partner for healthcare providers and patients across Europe.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.